Skip to main content

Advertisement

SpringerLink
Log in

Molecular Characteristics of Large Parathyroid Adenomas

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Introduction

The clinical entity of large parathyroid adenomas (LPTAs) has not been well defined. It is speculated that LPTAs would have biochemical, histological, and molecular characteristics different from small adenomas. Our study aimed to find out occurrence of atypia and carcinomas in large parathyroid lesions and the presence of distinct molecular abnormalities in LPTAs.

Materials and methods

We divided the parathyroid lesions into large (>7 g, i.e., LPTAs) and small (<7 g) adenomas. We performed parafibromin, APC (adenomatous polyposis coli), galectin 3, and PGP9.5 (protein gene product 9.5) analysis by immunohistochemistry in adenomas without atypia, atypical adenomas, and carcinomas.

Results

Mean serum calcium, alkaline phosphatase, and intact PTH were significantly higher in large parathyroid tumor group. The presence of both atypical adenoma and carcinoma was higher in large parathyroid tumor group. There was higher percentage of atypia in patients with LPTAs >10 g (33 %), and 68 % of tumors showed at least one marker suggestive of malignancy in this group. Detailed analysis of immunohistochemical features of LPTA >10 g revealed that six patients showed complete loss of parafibromin immunoreactivity (out of these four showed atypia), while seven showed partial loss. In histopathologically proven malignancy (n = 9), six patients showed complete loss of parafibromin staining, 5 (55 %) APC negativity, and 45 % showed both galectin 3 and PGP9.5 positivity. Three out of these showed all IHC markers s/o malignancy, and all of them had evidence of metastases or recurrence. 32 % of atypical adenoma and 13 % of atypical adenoma showed complete loss of parafibromin staining, however none developed metastases or recurrence in follow-up (median follow-up 40 months). Loss of parafibromin staining (complete or partial) was higher in LPTA group (56 %) than that in small adenoma (39 %); however, it was not statistically significant. APC, galectin 3, and PGP9.5 markers suggestive were higher in LPTA group but were not significant.

Conclusion

LPTAs may show some morphological and immunohistochemical features suggestive of malignancy and can be considered a separate entity. However, the immunohistochemical markers are unable to clearly segregate those LPTAs that may show premalignant potential. Further, we would like to recommend that LPTAs showing complete parafibromin loss together with atypia should be kept under close follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mishra SK, Agarwal G, Kar DK, Gupta SK, Mithal A, Rastad J (2001) Unique clinical characteristics of primary hyperparathyroidism in India. Br J Surg 88(5):708–714

    Article  CAS  PubMed  Google Scholar 

  2. Agarwal A, Mishra SK, Gujral RB (1998) Advanced skeletal manifestations in primary hyperparathyroidism. Can J Surg 41(5):342–343

    PubMed Central  CAS  PubMed  Google Scholar 

  3. Shah VN, Bhadada S, Bhansali A, Behera A, Mittal BR (2014) Changes in clinical & biochemical presentations of primary hyperparathyroidism in India over a period of 20 years. Indian J Med Res 139(5):694–699

    PubMed Central  PubMed  Google Scholar 

  4. Agarwal A, Gupta SK, Sukumar R (2009) Hyperparathyroidism and malnutrition with severe vitamin D deficiency. World J Surg 33(11):2303–2313. doi:10.1007/s00268-009-0044-0

    Article  PubMed  Google Scholar 

  5. Singh DN, Gupta SK, Kumari N, Krishnani N, Chand G, Mishra A, Agarwal G, Verma AK, Mishra SK, Agarwal A (2015) Primary hyperparathyroidism presenting as hypercalcemic crisis: twenty-year experience. Indian J Endocrinol Metab 19(1):100–105

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Agarwal G, Prasad KK, Kar DK, Krishnani N, Pandey R, Mishra SK (2006) Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinic investigative characteristics from those with benign parathyroid pathology. World J Surg 30(5):732–742. doi:10.4103/2230-8210.117222

    Article  PubMed  Google Scholar 

  7. Sulaiman L, Nilsson IL, Juhlin CC, Haglund F, Höög A, Larsson C, Hashemi J (2012) Genetic characterization of large parathyroid adenomas. Endocr Relat Cancer 19(3):389–407

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Bondeson L, Sandelin K, Grimelius L (1993) Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 17(8):820–829

    Article  CAS  PubMed  Google Scholar 

  9. Shane E (2001) Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86:485–493

    Article  CAS  PubMed  Google Scholar 

  10. Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, Robinson BG, Teh BT, Gimm O, Marsh DJ (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94(2):434–441

    Article  CAS  PubMed  Google Scholar 

  11. Hubbard J, Inabnet WB, Lo CY (2009) Endocrine surgery: principles and practice. Springer Science & Business Media, London, p 325

    Book  Google Scholar 

  12. O’Neal P, Mowschenson P, Connolly J, Hasselgren PO (2011) Large parathyroid tumors have an increased risk of atypia and carcinoma. Am J Surg 202:146–150

    Article  PubMed  Google Scholar 

  13. Bindlish V, Freeman JL, Witterick IJ, Asa SL (2002) Correlation of biochemical parameters with single parathyroid adenoma weight and volume. Head Neck 24:1000–1003

    Article  PubMed  Google Scholar 

  14. Moretz WH, Watts TL, Virgin FW, Chin E, Gourin CG, Terris DJ (2007) Correlation of intraoperative parathyroid hormone levels with parathyroid gland size. Laryngoscope 117:1957–1960

    Article  CAS  PubMed  Google Scholar 

  15. Randhawa PS, Mace AD, Nouraei SAR, Stearns MP (2007) Primary hyperparathyroidism: do perioperative biochemical variables correlate with parathyroid adenoma weight or volume? Clin Otolaryngol 32:179–184

    Article  CAS  PubMed  Google Scholar 

  16. De Lellis RA (2011) Parathyroid tumors and related disorders. Mod Pathol 24:S78–S93

    Article  Google Scholar 

  17. Fernandez-Ranvier GG, Khanafshar E, Jensen K, Jensen K, Zarnegar R, Lee J, Kebebew E, Duh QY, Clark OH (2007) Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer 110:255–264

    Article  PubMed  Google Scholar 

  18. Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21(3):166–177

    Article  CAS  PubMed  Google Scholar 

  19. Sandelin K, Tullgren O, Farnebo LO (1994) Clinical course of metastatic parathyroid cancer. World J Surg 18(4):594–598. doi:10.1016/j.clon.2010.04.007

    Article  CAS  PubMed  Google Scholar 

  20. Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A (1994) p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 78:1320–1324

    CAS  PubMed  Google Scholar 

  21. Cetani F, Pardi E, ViacavaP Pollina GD, Fanelli G, Picone A, Borsari S, Gazzerro E, Miccoli P, Berti P, Pinchera A, Marcocci C (2004) A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 60:99–106

    Article  CAS  Google Scholar 

  22. Lloyd RV, Carney JA, Ferreiro JA, Jin L, Thompson GB, Van Heerden JA, Grant CS, Wollan PC (1995) Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol 6(4):279–287

    Article  PubMed  Google Scholar 

  23. Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21(3):166–177

    Article  CAS  PubMed  Google Scholar 

  24. Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M (2005) Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 36(8):908–914

    Article  CAS  PubMed  Google Scholar 

  25. Tezel E, Hibi K, Nagasaka T, Nakao A (2000) PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 6(12):4764–4767

    CAS  PubMed  Google Scholar 

  26. Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Nakata Y, Kuma K, Amino N (2004) PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma. Eur J Cancer 40(4):614–618

    Article  CAS  PubMed  Google Scholar 

  27. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A (2002) PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 8(1):192–195

    CAS  PubMed  Google Scholar 

  28. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, SoodR Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Höög A, Heath H 3rd, James-Newton LA, Robinson B, ZarboRJ Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32:676–680

    Article  CAS  PubMed  Google Scholar 

  29. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722–1729

    Article  CAS  PubMed  Google Scholar 

  30. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40:657–663

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah WK, Cao B, Resau J, Morreau H, Teh BT (2004) Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10:6629–6637

    Article  CAS  PubMed  Google Scholar 

  32. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30(9):1140–1149

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was possible due to grant-in-aid from the Intramural research fund of SGPGIMS, Lucknow, India.

Author information

Author notes

    Authors and Affiliations

    1. Department of Endocrine Surgery, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, 226014, India

      Amit Agarwal, Roma Pradhan, Gyan Chand, A. Mishra, Gaurav Agarwal, Ashok Kumar Verma & Saroj Kanta Mishra

    2. Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

      Niraj Kumari, Narendra Krishnani & Pooja Shukla

    3. Department of Endocrinology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

      Sushil Kumar Gupta

    Authors
    1. Amit Agarwal
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Roma Pradhan
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Niraj Kumari
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Narendra Krishnani
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Pooja Shukla
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Sushil Kumar Gupta
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Gyan Chand
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. A. Mishra
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Gaurav Agarwal
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Ashok Kumar Verma
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Saroj Kanta Mishra
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Amit Agarwal.

    Additional information

    Amit Agarwal and Roma Pradhan have contributed equally to the manuscript.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Agarwal, A., Pradhan, R., Kumari, N. et al. Molecular Characteristics of Large Parathyroid Adenomas. World J Surg 40, 607–614 (2016). https://doi.org/10.1007/s00268-015-3380-2

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00268-015-3380-2

    Keywords

    Search

    Navigation